Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 660Carcinoma, Non-Small-Cell Lung 454Prostatic Neoplasms 384Neoplasms 376Lung Neoplasms 261Multiple Myeloma 246Colorectal Neoplasms 231Neoplasm Metastasis 214Melanoma 202Leukemia, Myeloid, Acute 165Ovarian Neoplasms 163Pancreatic Neoplasms 155Carcinoma, Renal Cell 141Squamous Cell Carcinoma of Head and Neck 137Lymphoma 134Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 123Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 117Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 107Stomach Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 100Hematologic Neoplasms 99Lymphoma, Follicular 95Sarcoma 93

Interventions

pembrolizumab 1Taxes 1Panitumumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Edema × 1 year × Clear all
NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
71 enrolled 11 charts
Breast

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡